Manmeet Ahluwalia, MD, MBA, chief, Solid Tumor Medical Oncology; deputy director; and chief scientific officer at Miami Cancer Institute, addressed disparities in genomic testing among minority patients with cancer, as well as equitable care strategies at his organization’s Center for Equity in Cancer Care & Research.
Every patient who is seen at Miami Cancer Institute is offered genomic testing of their tumor, which can then match each individual with the best standard-of-care treatment or a clinical trial that is open at our facility, said Manmeet Ahluwalia, MD, MBA, chief, Solid Tumor Medical Oncology; deputy director; and chief scientific officer at Miami Cancer Institute.
Transcript
What potential changes are being explored at Miami Cancer Institute’s Center for Equity in Cancer Care & Research as it pertains to how cancer care is delivered in and away from the clinic?
As we are all aware, there have been tremendous strides in cancer care, but there are still disparities that exist between different groups. For example, if you look at genomic testing, which is a big emphasis of cancer care these days, when a patient with cancer comes, he or she needs to be tested for genetic changes that may have driven their cancer, which helps us pick the right therapies, often targeted therapies, which are designer drugs [that] go and target the pathway that is driving someone's cancer or pick the right immunotherapy to give to those patients.
What we have found out is that patients of minority origin typically undergo less genetic testing compared with White Caucasian patients. Hence, our center has partnered up with Caris Life Sciences, and every patient who is seen at Miami Cancer Institute is offered a genetic testing of their tumor. And then depending on what the report shows, they are then offered either the best standard-of-care treatment using targeted therapies or immunotherapies or offered a clinical trial that is open at our place. The emphasis is to bridge this gap of the minority in cancer care compared with the rest of the community.
Also, we do know that social determinants of health play a big role in outcomes of the patients. And for that regard, we are working with community health care workers, launching cancer screening programs, to make sure that everyone has access to the best screening possible, but also everyone has access to the best cancer care if they are diagnosed with cancer. And this also includes access to clinical trials for all of our patients.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More